Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

Autor:	M. Rosales, Kian-Huat Lim, A. Wynter-Horton, K.-W. Lee, Y.-J. Bang, T. Wu, Jan Baughman, K. Huber, Haeseong Park, Philip J. Gold, Hope E. Uronis, Jan K Davidson-Moncada, Jill Lacy, Y-K. Kang, S.H. Park, Daniel Virgil Thomas Catenacci, M.C.H. Ng, Peter C. Enzinger, Jon M. Wigginton, J. Nordstrom
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry Surrogate endpoint Hematology Pembrolizumab Gastroesophageal Junction Adenocarcinoma Chemotherapy regimen Gastroenterology Ramucirumab Oncology Trastuzumab Internal medicine medicine Progression-free survival business Survival analysis medicine.drug
Zdroj:	Annals of Oncology. 30:v484-v485
ISSN:	0923-7534
DOI:	10.1093/annonc/mdz253.014
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b59b22375c9e2810aca705c5e4391c94 https://doi.org/10.1093/annonc/mdz253.014 Zobrazit plný text záznamu